| Year |
Citation |
Score |
| 2023 |
Ray U, Thirusangu P, Jin L, Xiao Y, Pathoulas CL, Staub J, Erskine CL, Dredge K, Hammond E, Block MS, Kaufmann SH, Bakkum-Gamez JN, Shridhar V. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction. Oncogene. 42: 2725-2736. PMID 37550562 DOI: 10.1038/s41388-023-02785-5 |
0.311 |
|
| 2021 |
Schroeder B, Vander Steen T, Espinoza I, Venkatapoorna CMK, Hu Z, Silva FM, Regan K, Cuyàs E, Meng XW, Verdura S, Arbusà A, Schneider PA, Flatten KS, Kemble G, Montero J, ... Kaufmann SH, et al. Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells. Cell Death & Disease. 12: 977. PMID 34675185 DOI: 10.1038/s41419-021-04262-x |
0.324 |
|
| 2021 |
Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, ... ... Kaufmann SH, et al. TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia. Cancer Discovery. 2: 162-185. PMID 34233272 DOI: 10.1158/2643-3230.BCD-20-0029 |
0.614 |
|
| 2021 |
Yun S, Vincelette ND, Yu X, Watson GW, Fernandez MR, Yang C, Hitosugi T, Cheng CH, Freischel AR, Zhang L, Li W, Hou H, Schaub FX, Vedder AR, Cen L, ... ... Kaufmann SH, et al. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia. Blood Cancer Discovery. 2: 162-185. PMID 33860275 DOI: 10.1158/2643-3230.bcd-20-0029 |
0.622 |
|
| 2021 |
Ding H, Vincelette ND, McGehee CD, Kohorst MA, Koh BD, Venkatachalam A, Meng XW, Schneider PA, Flatten KS, Peterson KL, Correia C, Lee SH, Patnaik M, Webster JA, Ghiaur G, ... ... Kaufmann SH, et al. CDK2-mediated upregulation of TNFa as a mechanism of selective cytotoxicity in acute leukemia. Cancer Research. PMID 33414171 DOI: 10.1158/0008-5472.CAN-20-1504 |
0.334 |
|
| 2020 |
Stenzel AE, Abrams SI, Joseph JM, Goode EL, Tario JD, Wallace PK, Kaur D, Adamson AK, Buas MF, Lugade AA, Laslavic A, Taylor SE, Orr B, Edwards RP, Elishaev E, ... ... Kaufmann SH, et al. Circulating CD14 HLA-DR monocytic cells as a biomarker for epithelial ovarian cancer progression. American Journal of Reproductive Immunology (New York, N.Y. : 1989). e13343. PMID 32905653 DOI: 10.1111/Aji.13343 |
0.317 |
|
| 2020 |
Ye K, Meng WX, Sun H, Wu B, Chen M, Pang YP, Gao J, Wang H, Wang J, Kaufmann SH, Dai H. Characterization of an alternative BAK-binding site for BH3 peptides. Nature Communications. 11: 3301. PMID 32620849 DOI: 10.1038/S41467-020-17074-Y |
0.33 |
|
| 2020 |
Dai H, Meng XW, Kaufmann SH. Selective Inhibition of BFL1: It's All about Finding the Right Partner. Cell Chemical Biology. 27: 639-642. PMID 32559500 DOI: 10.1016/J.Chembiol.2020.05.014 |
0.316 |
|
| 2020 |
Kojima Y, Machida Y, Palani S, Caulfield TR, Radisky ES, Kaufmann SH, Machida YJ. FAM111A protects replication forks from protein obstacles via its trypsin-like domain. Nature Communications. 11: 1318. PMID 32165630 DOI: 10.1038/S41467-020-15170-7 |
0.332 |
|
| 2020 |
Harris RS, Serebrenik AA, Argyris P, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Oberg AL, Hou X, Weroha SJ, Kaufmann SH, et al. The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32060098 DOI: 10.1158/1078-0432.Ccr-19-2786 |
0.348 |
|
| 2020 |
Yun S, Vincelette ND, Fernandez M, Yu X, Yang C, Hitosugi T, Cheng C, Freischel A, Zhang L, Watson G, Li W, Hou H, Schaub FX, Vedder A, Cen L, ... ... Kaufmann SH, et al. Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation Blood. 136: 12-13. DOI: 10.1182/BLOOD-2020-137209 |
0.639 |
|
| 2020 |
Kennedy JJ, Chowdhury S, Savage SR, Hou X, Huntoon CJ, Ivey RG, Yu Q, Lin C, Huang D, Zhao L, Voytovich UJ, Schoenherr RM, Shire Z, Skates SJ, Whiteaker JR, ... ... Kaufmann SH, et al. Abstract PR02: Proteogenomic approach to identify mechanisms of platinum refractoriness in high-grade serous ovarian cancers Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-Pr02 |
0.352 |
|
| 2020 |
Koubek EJ, Costello BA, Yin J, McGovern RM, Buhrow SA, Schoon RA, Strand CA, Jiang Y, Borad MJ, Takebe N, Kaufmann SH, Adjei AA, Reid JM. Abstract CT114: Pharmacokinetic analysis of navitoclax in combination with sorafenib in patients with relapsed or refractory solid organ tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct114 |
0.358 |
|
| 2019 |
Kanakkanthara A, Kurmi K, Ekstrom TL, Hou X, Purfeerst ER, Heinzen EP, Correia C, Huntoon CJ, O'Brien D, Wahner Hendrickson AE, Dowdy SC, Li H, Oberg AL, Hitosugi T, Kaufmann SH, et al. BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents. Cancer Research. PMID 31619387 DOI: 10.1158/0008-5472.Can-19-1405 |
0.336 |
|
| 2019 |
Kanakkanthara A, Huntoon CJ, Hou X, Zhang M, Heinzen EP, O'Brien DR, Oberg AL, John Weroha S, Kaufmann SH, Karnitz LM. ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer. Nature Communications. 10: 4632. PMID 31604914 DOI: 10.1038/S41467-019-12610-X |
0.361 |
|
| 2019 |
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, ... ... Kaufmann SH, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. The Lancet. Oncology. PMID 30880072 DOI: 10.1016/S1470-2045(18)30905-7 |
0.359 |
|
| 2019 |
Vincelette ND, Ding H, Huehls AM, Flatten KS, Kelly RL, Kohorst MA, Webster J, Hess AD, Pratz KW, Karnitz LM, Kaufmann SH. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo. Scientific Reports. 9: 3617. PMID 30837643 DOI: 10.1038/S41598-019-40218-0 |
0.43 |
|
| 2019 |
Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, ... ... Kaufmann SH, et al. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology. PMID 30686551 DOI: 10.1016/J.Ygyno.2019.01.015 |
0.363 |
|
| 2019 |
Al-Kali A, Aldoss I, Strand C, Shah BD, Webster JA, Bhatnagar B, Akhtari M, Doyle LA, Kaufmann SH. A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis. Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.15_Suppl.E18506 |
0.331 |
|
| 2019 |
Carr RM, Lasho T, Marks D, Tolosa E, Almada LL, Alver B, Binder M, Safgren S, Horn I, Berger K, Mangaonkar AA, Antelo GB, Coltro G, Pin C, Witzig TE, ... ... Kaufmann SH, et al. Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures Blood. 134: 1710-1710. DOI: 10.1182/Blood-2019-123877 |
0.312 |
|
| 2018 |
Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, ... Kaufmann SH, et al. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery. PMID 30425037 DOI: 10.1158/2159-8290.Cd-18-0715 |
0.324 |
|
| 2018 |
Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, et al. A Randomized Trial of Three Novel Regimens for Recurrent Acute Myeloid Leukemia Demonstrates the Continuing Challenge of Treating this Difficult Disease. American Journal of Hematology. PMID 30370956 DOI: 10.1002/Ajh.25333 |
0.304 |
|
| 2018 |
Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, ... ... Kaufmann SH, et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications. 9: 3970. PMID 30266954 DOI: 10.1038/S41467-018-05564-Z |
0.306 |
|
| 2018 |
Kurmi K, Hitosugi S, Yu J, Boakye-Agyeman F, Wiese EK, Larson TR, Dai Q, Machida YJ, Lou Z, Wang L, Boughey JC, Kaufmann SH, Goetz MP, Karnitz LM, Hitosugi T. Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway. Cell Metabolism. PMID 30174304 DOI: 10.1016/J.Cmet.2018.08.008 |
0.33 |
|
| 2018 |
Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Rizvi S, Kaufmann SH, Gores GJ. Fibroblast Growth Factor Receptor Inhibition induces loss of matrix MCL1 and necrosis in Cholangiocarcinoma. Journal of Hepatology. PMID 29408314 DOI: 10.1016/J.Jhep.2018.01.026 |
0.374 |
|
| 2018 |
Hurley RM, Hendrickson AEW, Visscher DW, Ansell PJ, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Jonge MJD, Herpen CMLV, Gietema JA, Koornstra RHT, Jager A, ... ... Kaufmann SH, et al. 53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Journal of Clinical Oncology. 36: 5538-5538. DOI: 10.1200/Jco.2018.36.15_Suppl.5538 |
0.337 |
|
| 2018 |
Hurley RM, Nesic K, McGehee C, Kondrashova O, Harrell MI, Schneider PA, Hou X, Correia C, Flatten KS, Zapparoli GV, Dobrovic A, Lin KK, Harding TC, Hendrickson AEW, Swisher EM, ... ... Kaufmann SH, et al. Abstract 5885: Loss of RAD51C promoter hypermethylation confers PARP inhibitor resistance Cancer Research. 78: 5885-5885. DOI: 10.1158/1538-7445.Am2018-5885 |
0.326 |
|
| 2017 |
Sterner RM, Kremer KN, Al-Kali A, Patnaik MM, Gangat N, Litzow MR, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE. Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget. 8: 94569-94579. PMID 29212250 DOI: 10.18632/Oncotarget.21809 |
0.361 |
|
| 2017 |
Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred JB, Lensing JL, ... ... Kaufmann SH, et al. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29138343 DOI: 10.1158/1078-0432.Ccr-17-1590 |
0.324 |
|
| 2017 |
Wahner Hendrickson AE, Kaufmann SH, Swisher EM. Doubling Down on BRCA-Mutated Cancer. Trends in Cancer. 3: 743-744. PMID 29120748 DOI: 10.1016/J.Trecan.2017.09.005 |
0.302 |
|
| 2017 |
Dai H, Ding H, Peterson KL, Meng XW, Schneider PA, Knorr KLB, Kaufmann SH. Measurement of BH3-only protein tolerance. Cell Death and Differentiation. PMID 29053140 DOI: 10.1038/Cdd.2017.156 |
0.358 |
|
| 2017 |
Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, et al. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leukemia Research. 61: 108-116. PMID 28957699 DOI: 10.1016/J.Leukres.2017.09.005 |
0.346 |
|
| 2017 |
Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, ... ... Kaufmann SH, et al. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma. Cancer Discovery. PMID 28588062 DOI: 10.1158/2159-8290.Cd-17-0419 |
0.311 |
|
| 2017 |
Kaufmann SH, Hendrickson AEW, Harrell MI, Menefee ME, Tanner EJ, Mutch DG, Swisher EM, Karnitz LM. Abstract IS04: PARP INHIBITOR COMBINATIONS FOR THE TREATMENT OF OVARIAN CANCER Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Is04 |
0.372 |
|
| 2017 |
Swisher E, Harrell M, Lin KK, Scott C, Goble S, Oza A, Coleman RL, Konecny G, Tinker AV, O'Malley DM, Kristeleit R, Ma L, Brenton J, Bell-McGuinn K, Oaknin A, ... ... Kaufmann SH, et al. Abstract AP28: BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Ap28 |
0.317 |
|
| 2017 |
Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Farooq S, Cadoo K, Whalen C, Luo W, Liu H, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, ... ... Kaufmann SH, et al. Abstract CT008: Phase I study of the alpha specific PI3-Kinase inhibitor BYL719 and the poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib in recurrent ovarian and breast cancer: Analysis of the dose escalation and ovarian cancer expansion cohort Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct008 |
0.359 |
|
| 2017 |
Hendrickson AEW, Lin KK, Visscher DW, Hurley RM, Raponi M, Harding TC, Murphy LM, Wagner JM, Giordano H, McNeish I, Swisher EM, Kaufmann S. Abstract 4676: DNA repair protein expression and response of homologous recombination deficient ovarian cancer to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in the ARIEL2 Part 1 study Cancer Research. 77: 4676-4676. DOI: 10.1158/1538-7445.Am2017-4676 |
0.354 |
|
| 2017 |
Swisher EM, Harrell MI, Lin K, Coleman RL, Konecny GE, Tinker AV, O'Malley DM, McNeish I, Kaufmann SH. BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1 Gynecologic Oncology. 145: 5. DOI: 10.1016/J.Ygyno.2017.03.034 |
0.313 |
|
| 2016 |
Dai H, Meng XW, Kaufmann SH. Mitochondrial apoptosis and BH3 mimetics. F1000research. 5: 2804. PMID 27990281 DOI: 10.12688/F1000Research.9629.1 |
0.352 |
|
| 2016 |
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, ... ... Kaufmann SH, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. The Lancet. Oncology. PMID 27908594 DOI: 10.1016/S1470-2045(16)30559-9 |
0.317 |
|
| 2016 |
Ding H, Peterson KL, Correia C, Koh B, Schneider PA, Nowakowski GS, Kaufmann SH. Histone deacetylase inhibitors interrupt HSP90 RASGRP1 and HSP90 CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells. Leukemia. PMID 27890930 DOI: 10.1038/Leu.2016.357 |
0.413 |
|
| 2016 |
AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, ... ... Kaufmann SH, et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecologic Oncology. PMID 27614696 DOI: 10.1016/J.Ygyno.2016.08.328 |
0.35 |
|
| 2016 |
Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji JJ, Karnitz L, Herman JG, Kinders R, Smith BD, Gore SD, Carraway H, Showel MM, Gladstone DE, Levis MJ, ... ... Kaufmann SH, et al. A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27551000 DOI: 10.1158/1078-0432.Ccr-16-1274 |
0.366 |
|
| 2016 |
Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway H, Showel MM, Levis MJ, Dezern A, Gladstone DE, Ji JJ, Wang L, ... ... Kaufmann SH, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27503200 DOI: 10.1158/1078-0432.Ccr-16-0984 |
0.359 |
|
| 2016 |
Leonard B, Starrett GJ, Maurer MJ, Oberg A, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson B, Brown WL, Kalli KR, Kaufmann SH, et al. APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27016308 DOI: 10.1158/1078-0432.Ccr-15-2910 |
0.338 |
|
| 2016 |
Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp J, Swisher EM, McDevett M, Kaufmann SH. Poly(ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26979391 DOI: 10.1158/1078-0432.Ccr-15-2351 |
0.379 |
|
| 2016 |
Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Wahner Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH. 4EBP1/c-MYC/PUMA and NFκB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. Blood. PMID 26917778 DOI: 10.1182/Blood-2015-02-629485 |
0.688 |
|
| 2016 |
Zhang H, Liu H, Chen Y, Yang X, Wang P, Liu T, Deng M, Qin B, Correia C, Lee S, Kim J, Sparks M, Nair AA, Evans DL, Kalari KR, ... ... Kaufmann SH, et al. A cell cycle-dependent BRCA1-UHRF1 cascade regulates DNA double-strand break repair pathway choice. Nature Communications. 7: 10201. PMID 26727879 DOI: 10.1038/Ncomms10201 |
0.305 |
|
| 2016 |
Dai H, Meng XW, Kaufmann SH. BCL2 Family, Mitochondrial Apoptosis, and Beyond Cancer Translational Medicine. 2: 7. DOI: 10.4103/2395-3977.177558 |
0.391 |
|
| 2016 |
Nitschmann CC, Hurley RM, Becker MA, Hou X, Hoch U, Harding TC, Charych DH, Kaufmann SH, Haluska P, Weroha SJ. Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B50 |
0.364 |
|
| 2016 |
Sterner R, Kremer K, Dudakovic A, Kaufmann S, Westendorf J, Wijnen Av, Hedin K. Abstract 3292: Manipulating osteoblast differentiation in order to inhibit protection of AML cells within the bone marrow Cancer Research. 76: 3292-3292. DOI: 10.1158/1538-7445.Am2016-3292 |
0.346 |
|
| 2016 |
Sanjiv K, Gad H, Rudd S, Hurley R, Herr P, Montaño JMC, Mortusewicz O, Koolmeister T, Jaques S, Morón EB, Hoglund A, Lee T, Scobie M, Kaufmann S, Weroha J, et al. Abstract 1260: Polymerase kappa determines the sensitivity of MTH1 inhibitors to cisplatin-resistant cell Cancer Research. 76: 1260-1260. DOI: 10.1158/1538-7445.Am2016-1260 |
0.345 |
|
| 2015 |
Dai H, Ding H, Meng XW, Peterson KL, Schneider PA, Karp JE, Kaufmann SH. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes & Development. 29: 2140-52. PMID 26494789 DOI: 10.1101/Gad.267997.115 |
0.432 |
|
| 2015 |
Kremer KN, Dudakovic A, Hess AD, Smith BD, Karp JE, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE. Histone deacetylase inhibitors target the leukemic microenvironment by enhancing a Nherf1-Protein Phosphatase 1α-TAZ signaling pathway in osteoblasts. The Journal of Biological Chemistry. PMID 26491017 DOI: 10.1074/Jbc.M115.668160 |
0.404 |
|
| 2015 |
Knorr KL, Schneider PA, Meng XW, Dai H, Smith BD, Hess AD, Karp JE, Kaufmann SH. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors. Cell Death and Differentiation. PMID 26045051 DOI: 10.1038/Cdd.2015.74 |
0.445 |
|
| 2015 |
Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, Nowakowski GS, Dai H, Kaufmann SH. Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment. Biochimica Et Biophysica Acta. 1853: 1658-1671. PMID 25827952 DOI: 10.1016/J.Bbamcr.2015.03.012 |
0.355 |
|
| 2015 |
Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1397-406. PMID 25779564 DOI: 10.1200/Jco.2014.58.8848 |
0.368 |
|
| 2015 |
Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, ... ... Kaufmann SH, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 125: 658-67. PMID 25452615 DOI: 10.1182/Blood-2014-04-571786 |
0.306 |
|
| 2015 |
Hendrickson AEW, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Flatten KS, Poirier GG, Lensing J, Erlichman C, Kaufmann SH, Haluska P. A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps2618 |
0.359 |
|
| 2015 |
Yun S, Vincelette ND, Knorr KLB, Almada LL, Schneider PA, Peterson KL, Flatten KS, Hess AD, Smith BD, Karp JE, Fernandez-Zapico ME, Kaufmann SH. mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies Blood. 126: 3705-3705. DOI: 10.1182/Blood.V126.23.3705.3705 |
0.698 |
|
| 2015 |
Webster JA, Tibes R, Blackford A, Morris L, Patnaik MM, Wang L, Rebechi M, Greer J, Litzow MR, Karnitz L, Rosner GL, Doyle A, Kaufmann SH, Karp JE, Smith BD. Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia Blood. 126: 2563-2563. DOI: 10.1182/Blood.V126.23.2563.2563 |
0.368 |
|
| 2015 |
Gojo I, Beumer JH, Pratz K, Ji J, Wang L, Rudek MA, McDevitt MA, Baer MR, Blackford A, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, DeZern AE, ... ... Kaufmann SH, et al. A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias Blood. 126: 1361-1361. DOI: 10.1182/Blood.V126.23.1361.1361 |
0.334 |
|
| 2015 |
Shah MV, Flatten KS, Smith BD, Hess AD, Kaufmann SH. MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia Blood. 126: 1273-1273. DOI: 10.1182/Blood.V126.23.1273.1273 |
0.444 |
|
| 2015 |
Vincelette ND, Karnitz LM, Karp JE, Smith DB, Hess AD, Mayer LD, Kaufmann SH. Abstract 3479: CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition Cancer Research. 75: 3479-3479. DOI: 10.1158/1538-7445.Am2015-3479 |
0.434 |
|
| 2014 |
Samejima K, Ogawa H, Ageichik AV, Peterson KL, Kaufmann SH, Kanemaki MT, Earnshaw WC. Auxin-induced rapid degradation of inhibitor of caspase-activated DNase (ICAD) induces apoptotic DNA fragmentation, caspase activation, and cell death: a cell suicide module. The Journal of Biological Chemistry. 289: 31617-23. PMID 25248749 DOI: 10.1074/Jbc.M114.583542 |
0.411 |
|
| 2014 |
Sainski AM, Dai H, Natesampillai S, Pang YP, Bren GD, Cummins NW, Correia C, Meng XW, Tarara JE, Ramirez-Alvarado M, Katzmann DJ, Ochsenbauer C, Kappes JC, Kaufmann SH, Badley AD. Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. The Journal of Cell Biology. 206: 867-76. PMID 25246614 DOI: 10.1083/Jcb.201405051 |
0.335 |
|
| 2014 |
Rizvi S, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. The Journal of Biological Chemistry. 289: 22835-49. PMID 24973208 DOI: 10.1074/Jbc.M114.563064 |
0.443 |
|
| 2014 |
Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, Hess AD, Smith BD, Karp JE, Kaufmann SH. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression. The Journal of Biological Chemistry. 289: 20543-58. PMID 24895135 DOI: 10.1074/Jbc.M114.549220 |
0.442 |
|
| 2014 |
Kremer KN, Dudakovic A, McGee-Lawrence ME, Philips RL, Hess AD, Smith BD, van Wijnen AJ, Karp JE, Kaufmann SH, Westendorf JJ, Hedin KE. Osteoblasts protect AML cells from SDF-1-induced apoptosis. Journal of Cellular Biochemistry. 115: 1128-37. PMID 24851270 DOI: 10.1002/Jcb.24755 |
0.377 |
|
| 2014 |
Zhang JS, Herreros-Villanueva M, Herreros-Vilanueva M, Koenig A, Deng Z, de Narvajas AA, Gomez TS, Meng X, Bujanda L, Ellenrieder V, Li XK, Kaufmann SH, Billadeau DD. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Cell Death & Disease. 5: e1142. PMID 24675460 DOI: 10.1038/Cddis.2014.102 |
0.402 |
|
| 2014 |
He X, Khurana A, Roy D, Kaufmann S, Shridhar V. Loss of HSulf-1 expression enhances tumorigenicity by inhibiting Bim expression in ovarian cancer. International Journal of Cancer. Journal International Du Cancer. 135: 1783-9. PMID 24596063 DOI: 10.1002/Ijc.28818 |
0.376 |
|
| 2014 |
Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH. Context-dependent antagonism between Akt inhibitors and topoisomerase poisons. Molecular Pharmacology. 85: 723-34. PMID 24569089 DOI: 10.1124/Mol.113.088674 |
0.415 |
|
| 2014 |
Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, ... ... Kaufmann SH, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1288-97. PMID 24398046 DOI: 10.1158/1078-0432.Ccr-13-2611 |
0.302 |
|
| 2014 |
Dai H, Pang YP, Ramirez-Alvarado M, Kaufmann SH. Evaluation of the BH3-only protein Puma as a direct Bak activator. The Journal of Biological Chemistry. 289: 89-99. PMID 24265320 DOI: 10.1074/Jbc.M113.505701 |
0.372 |
|
| 2014 |
Chaudhuri L, Vincelette ND, Koh BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH, Tibes R. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo. Haematologica. 99: 688-96. PMID 24179152 DOI: 10.3324/Haematol.2013.093187 |
0.399 |
|
| 2014 |
Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH. Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. Haematologica. 99: 60-9. PMID 23996484 DOI: 10.3324/Haematol.2013.087734 |
0.684 |
|
| 2014 |
Swisher EM, McNeish IA, Coleman RL, Brenton J, Kaufmann SH, Allen AR, Raponi M, Giordano H, Maloney L, Isaacson J, Ledermann JA. ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5619 |
0.335 |
|
| 2014 |
Knorr KLB, Smith BD, Hess AD, Karp JE, Kaufmann SH. Investigation of MLN4924 Alone and in Combination with Bcl-2 Inhibitors in Hematopoietic Stem Cells and Progenitors in Acute Myelogenous Leukemia Blood. 124: 3603-3603. DOI: 10.1182/Blood.V124.21.3603.3603 |
0.446 |
|
| 2014 |
Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harell MI, Etemadmoghadam D, Galletta L, Alsop K, Mitchell G, Fox SB, ... ... Kaufmann SH, et al. Abstract 38: Using molecularly characterized patient-derived models to delineate underlying drivers and vulnerabilities of epithelial ovarian cancer Cancer Research. 74: 38-38. DOI: 10.1158/1538-7445.Cansusc14-38 |
0.343 |
|
| 2014 |
Swisher E, McNeish I, Coleman RL, Brenton JD, Kaufmann SH, Allen A, Raponi M, Giordano H, Maloney L, Isaacson J, Ledermann JA. Abstract CT339: Prospective molecular identification of ovarian cancer patients benefiting from PARP inhibitor (PARPi, rucaparib) maintenance therapy - reaching beyond germline BRCA mutations Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct339 |
0.329 |
|
| 2014 |
Zhang JS, Herreros-Villanueva M, Koenig A, Deng Z, Narvajas AAMD, Gomez TS, Meng X, Bujanda L, Ellenrieder V, Li XK, Kaufmann SH, Billadeau DD. Erratum: Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells (Cell Death and Disease (2014) 5 (e1142) DOI: 10.1038/cddis.2014.102) Cell Death and Disease. 5. DOI: 10.1038/Cddis.2014.341 |
0.391 |
|
| 2014 |
Tibes R, Chaudhuri L, Vincelette ND, Kohl BD, Naylor RM, Flatten KS, Peterson KL, McNally A, Gojo I, Karp JE, Mesa RA, Sproat LO, Bogenberger JM, Kaufmann SH. Chk1 and WEE1 Inhibition Combine Synergistically and Represent a Novel Non-cytotoxic Combination in Acute Myeloid Leukemia Clinical Lymphoma, Myeloma & Leukemia. 14. DOI: 10.1016/J.Clml.2014.06.053 |
0.338 |
|
| 2013 |
Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, ... ... Kaufmann SH, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Research. 73: 7222-31. PMID 24154874 DOI: 10.1158/0008-5472.Can-13-1753 |
0.316 |
|
| 2013 |
Dai H, Ding H, Meng XW, Lee SH, Schneider PA, Kaufmann SH. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Research. 73: 6998-7008. PMID 24097825 DOI: 10.1158/0008-5472.Can-13-0940 |
0.406 |
|
| 2013 |
De Lorenzo SB, Patel AG, Hurley RM, Kaufmann SH. The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Frontiers in Oncology. 3: 228. PMID 24062981 DOI: 10.3389/Fonc.2013.00228 |
0.376 |
|
| 2013 |
Kumar SK, Jett J, Marks R, Richardson R, Quevedo F, Moynihan T, Croghan G, Markovic SN, Bible KC, Qin R, Tan A, Molina J, Kaufmann SH, Erlichman C, Adjei AA. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs. 31: 1201-6. PMID 23887852 DOI: 10.1007/S10637-013-0004-2 |
0.34 |
|
| 2013 |
Kremer KN, Peterson KL, Schneider PA, Meng XW, Dai H, Hess AD, Smith BD, Rodriguez-Ramirez C, Karp JE, Kaufmann SH, Hedin KE. CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak. The Journal of Biological Chemistry. 288: 22899-914. PMID 23798675 DOI: 10.1074/Jbc.M113.449926 |
0.445 |
|
| 2013 |
Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. Cancer Research. 73: 3683-91. PMID 23548269 DOI: 10.1158/0008-5472.Can-13-0110 |
0.434 |
|
| 2013 |
Hendrickson AEW, Visscher DW, Goergen KM, Negron V, Lingle WL, Oberg AL, Kalli K, Hartmann LC, Maurer MJ, Kaufmann SH. The role of CHFR expression in ovarian cancer and response to taxane therapy. Journal of Clinical Oncology. 31: 5546-5546. DOI: 10.1200/Jco.2013.31.15_Suppl.5546 |
0.332 |
|
| 2013 |
Venkatapoorna CMK, Espinoza I, Kaufmann SH, Lupu R. Abstract 1737: Pharmacological inhibition of fatty acid synthase regulates BH3-only proteins and sensitizes breast cancer cells to a small molecule Bcl-2/Bcl-xL inhibitor to induce apoptosis. Cancer Research. 73: 1737-1737. DOI: 10.1158/1538-7445.Am2013-1737 |
0.43 |
|
| 2013 |
Hilli MA, Weroha SJ, Becker M, Hou X, Harrington S, McKinstrey S, Kalli K, Goodman K, Wilcoxen K, Swisher E, Kaufmann S, Haluska P. Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-Pr05 |
0.365 |
|
| 2012 |
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, ... ... Kaufmann SH, et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias Clinical Cancer Research. 18: 6723-6731. PMID 23092873 DOI: 10.1158/1078-0432.Ccr-12-2442 |
0.317 |
|
| 2012 |
Schenk EL, Koh BD, Flatten KS, Peterson KL, Parry D, Hess AD, Smith BD, Karp JE, Karnitz LM, Kaufmann SH. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro Clinical Cancer Research. 18: 5364-5373. PMID 22869869 DOI: 10.1158/1078-0432.Ccr-12-0961 |
0.428 |
|
| 2012 |
Pang YP, Dai H, Smith A, Meng XW, Schneider PA, Kaufmann SH. Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization. Scientific Reports. 2: 257. PMID 22355769 DOI: 10.1038/Srep00257 |
0.718 |
|
| 2012 |
Gores GJ, Kaufmann SH. Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors Genes and Development. 26: 305-311. PMID 22345513 DOI: 10.1101/Gad.186189.111 |
0.358 |
|
| 2012 |
Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1655-62. PMID 22291137 DOI: 10.1158/1078-0432.Ccr-11-2890 |
0.433 |
|
| 2012 |
Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, Kaufmann SH. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. The Journal of Biological Chemistry. 287: 4198-210. PMID 22158865 DOI: 10.1074/Jbc.M111.296475 |
0.419 |
|
| 2012 |
Gupta M, Hendrickson AE, Yun SS, Han JJ, Schneider PA, Koh BD, Stenson MJ, Wellik LE, Shing JC, Peterson KL, Flatten KS, Hess AD, Smith BD, Karp JE, Barr S, ... ... Kaufmann SH, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood. 119: 476-87. PMID 22080480 DOI: 10.1182/Blood-2011-04-346601 |
0.696 |
|
| 2012 |
Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecologic Oncology. 124: 210-5. PMID 22047770 DOI: 10.1016/J.Ygyno.2011.10.002 |
0.37 |
|
| 2012 |
Topp M, Hartley L, Cook M, Etemadmoghadam D, Galleta L, Pyman J, McNally O, Haluska P, Swisher EM, Kaufmann SH, Wakefield M, Bowtell D, Scott CL. Targeting therapy based on preclinical analysis of clinical, molecular, and functional characteristics of individual high-grade serous ovarian cancers. Journal of Clinical Oncology. 30: 5073-5073. DOI: 10.1200/Jco.2012.30.15_Suppl.5073 |
0.326 |
|
| 2012 |
Lancet JE, Feldman E, Foster MC, Gojo I, Odenike O, Komrokji RS, Strair R, Kaufmann SH, Knoblauch R, Karkera JD, Wright JJ, Karp JE. Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Blood. 120: 1508-1508. DOI: 10.1182/Blood.V120.21.1508.1508 |
0.333 |
|
| 2012 |
He X, Khurana A, Kaufmann S, Shridhar V. Abstract 4179: Loss of Hsulf-1 promotes chemoresistance and tumorigenecity in ovarian cancer Cancer Research. 72: 4179-4179. DOI: 10.1158/1538-7445.Am2012-4179 |
0.422 |
|
| 2012 |
Pang YP, Dai H, Smith A, Meng XW, Schneider PA, Kaufmann SH. Bak conformational changes induced by ligand binding: Insight into BH3 domain binding and bak homo-oligomerization Scientific Reports. 2. DOI: 10.1038/srep00257 |
0.697 |
|
| 2011 |
Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ. Death receptor 5 signaling promotes hepatocyte lipoapoptosis. The Journal of Biological Chemistry. 286: 39336-48. PMID 21941003 DOI: 10.1074/Jbc.M111.280420 |
0.382 |
|
| 2011 |
Meng XW, Peterson KL, Dai H, Schneider P, Lee SH, Zhang JS, Koenig A, Bronk S, Billadeau DD, Gores GJ, Kaufmann SH. High cell surface death receptor expression determines type I versus type II signaling. The Journal of Biological Chemistry. 286: 35823-33. PMID 21865165 DOI: 10.1074/Jbc.M111.240432 |
0.329 |
|
| 2011 |
Schnepple DJ, Shepard B, Bren GD, Cummins NW, Natesampillai S, Trushin S, Algeciras-Schimnich A, Meng XW, Sainski AM, Rizza SA, Kaufmann SH, Badley AD. Isolation of a TRAIL antagonist from the serum of HIV-infected patients Journal of Biological Chemistry. 286: 35742-35754. PMID 21859711 DOI: 10.1074/Jbc.M111.274639 |
0.305 |
|
| 2011 |
Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 96: 1619-26. PMID 21791475 DOI: 10.3324/Haematol.2011.049551 |
0.348 |
|
| 2011 |
Dai H, Smith A, Meng XW, Schneider PA, Pang YP, Kaufmann SH. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization Journal of Cell Biology. 194: 39-48. PMID 21727192 DOI: 10.1083/Jcb.201102027 |
0.74 |
|
| 2011 |
Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, ... ... Kaufmann SH, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 118: 4882-9. PMID 21725056 DOI: 10.1182/Blood-2011-02-334904 |
0.353 |
|
| 2011 |
Ding H, Hackbarth J, Schneider PA, Peterson KL, Meng XW, Dai H, Witzig TE, Kaufmann SH. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation Blood. 118: 4872-4881. PMID 21673341 DOI: 10.1182/Blood-2011-02-334870 |
0.442 |
|
| 2011 |
Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Research. 71: 4944-54. PMID 21613406 DOI: 10.1158/0008-5472.Can-11-0814 |
0.399 |
|
| 2011 |
Smith AJ, Dai H, Correia C, Takahashi R, Lee SH, Schmitz I, Kaufmann SH. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells Journal of Biological Chemistry. 286: 17682-17692. PMID 21454712 DOI: 10.1074/Jbc.M110.189092 |
0.763 |
|
| 2011 |
Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells Proceedings of the National Academy of Sciences of the United States of America. 108: 3406-3411. PMID 21300883 DOI: 10.1073/Pnas.1013715108 |
0.42 |
|
| 2011 |
Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten Eyck C, Nakanishi T, Tibodeau JD, Ross DD, Gottardis MM, Erlichman C, Kaufmann SH, Haluska P. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Molecular Cancer Therapeutics. 10: 117-25. PMID 21220496 DOI: 10.1158/1535-7163.Mct-10-0438 |
0.346 |
|
| 2011 |
McDevitt MA, Koh BD, Patel A, Moliterno AR, Poh W, Herman JG, Dilley RL, Smith BD, Karp JE, Maciejewski JP, Kaufmann SH, Pratz KW. Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders Blood. 118: 400-400. DOI: 10.1182/Blood.V118.21.400.400 |
0.387 |
|
| 2011 |
Thomas BM, Kaufmann SH, Greer JM, Gore SD, Pratz KW, Smith BD, Mackey K, Loechner S, Horowitz JA, Karp JE. Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia Blood. 118: 1531-1531. DOI: 10.1182/Blood.V118.21.1531.1531 |
0.329 |
|
| 2010 |
Wagner JM, Kaufmann SH. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals (Basel, Switzerland). 3: 1311-1334. PMID 27713304 DOI: 10.3390/Ph3051311 |
0.355 |
|
| 2010 |
Huntoon CJ, Nye MD, Geng L, Peterson KL, Flatten KS, Haluska P, Kaufmann SH, Karnitz LM. Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway Cancer Research. 70: 8642-8650. PMID 20841485 DOI: 10.1158/0008-5472.Can-10-1345 |
0.37 |
|
| 2010 |
Sosa Seda IM, Mott JL, Akazawa Y, Barreyro FJ, Bronk SF, Kaufmann SH, Gores GJ. Noxa mediates hepatic stellate cell apoptosis by proteasome inhibition. Hepatology Research : the Official Journal of the Japan Society of Hepatology. 40: 701-10. PMID 20557369 DOI: 10.1111/J.1872-034X.2010.00668.X |
0.392 |
|
| 2010 |
Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. Nature Reviews. Cancer. 10: 293-301. PMID 20200537 DOI: 10.1038/Nrc2812 |
0.319 |
|
| 2010 |
Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH. Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. The Journal of Biological Chemistry. 285: 888-902. PMID 19887445 DOI: 10.1074/Jbc.M109.057638 |
0.421 |
|
| 2010 |
Pratz KW, Kaufmann SH, Litzow MR, Ji J, Chen A, Rudek MA, Karp JE. Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias, Blood. 118: 3634-3634. DOI: 10.1182/Blood.V118.21.3634.3634 |
0.319 |
|
| 2010 |
Hendrickson AEW, Gupta M, Yun S, Shing JC, Schneider PA, Peterson KL, Karp JE, Barr S, Witzig TE, Kaufmann SH. OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy Blood. 116: 970-970. DOI: 10.1182/Blood.V116.21.970.970 |
0.707 |
|
| 2010 |
Gupta M, Hendrickson AW, Han JJ, Stenson M, Wellik L, Barr S, Kaufmann SH, Witzig TE. Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKTS473 Phosphorylation by Potentiating AKT2-PHLPP1 Association Blood. 116: 772-772. DOI: 10.1182/Blood.V116.21.772.772 |
0.446 |
|
| 2010 |
Witzig TE, Hui T, Micallef IN, Ansell SM, Link B, Inwards DJ, Porrata L, Johnston PB, Colgan J, Markovic S, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Weiner G, ... ... Kaufmann SH, et al. A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas Blood. 116: 287-287. DOI: 10.1182/Blood.V116.21.287.287 |
0.361 |
|
| 2010 |
Rhodes DR, Kaufmann SH, Meng XW, Wyngaard P, Daubresse G, Leopold JS. Abstract A41: Somatic mutations in human cancer cell lines predict sorafenib response Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-A41 |
0.346 |
|
| 2009 |
Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Research. 69: 7635-43. PMID 19789352 DOI: 10.1158/0008-5472.Can-09-0511 |
0.346 |
|
| 2009 |
Masuoka HC, Mott J, Bronk SF, Werneburg NW, Akazawa Y, Kaufmann SH, Gores GJ. Mcl-1 degradation during hepatocyte lipoapoptosis. The Journal of Biological Chemistry. 284: 30039-48. PMID 19734538 DOI: 10.1074/Jbc.M109.039545 |
0.398 |
|
| 2009 |
Fu Z, Regan K, Zhang L, Muders MH, Thibodeau SN, French A, Wu Y, Kaufmann SH, Lingle WL, Chen J, Tindall DJ. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. The Journal of Clinical Investigation. 119: 2714-24. PMID 19690386 DOI: 10.1172/Jci37405 |
0.306 |
|
| 2009 |
Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood. 114: 2926-35. PMID 19641186 DOI: 10.1182/Blood-2009-05-220889 |
0.396 |
|
| 2009 |
Gálvez-Peralta M, Hackbarth JS, Flatten KS, Kaufmann SH, Hiasa H, Xing C, Ferguson DM. On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic & Medicinal Chemistry Letters. 19: 4459-62. PMID 19501511 DOI: 10.1016/J.Bmcl.2009.05.037 |
0.375 |
|
| 2009 |
Lewis KA, Lilly KK, Reynolds EA, Sullivan WP, Kaufmann SH, Cliby WA. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Molecular Cancer Therapeutics. 8: 855-63. PMID 19372558 DOI: 10.1158/1535-7163.Mct-08-1135 |
0.405 |
|
| 2009 |
Dai H, Meng XW, Lee SH, Schneider PA, Kaufmann SH. Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. The Journal of Biological Chemistry. 284: 18311-22. PMID 19351886 DOI: 10.1074/jbc.M109.004770 |
0.301 |
|
| 2009 |
Akazawa Y, Mott JL, Bronk SF, Werneburg NW, Kahraman A, Guicciardi ME, Meng XW, Kohno S, Shah VH, Kaufmann SH, McNiven MA, Gores GJ. Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology. 136: 2365-2376.e1-7. PMID 19272388 DOI: 10.1053/J.Gastro.2009.02.071 |
0.385 |
|
| 2009 |
Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, ... ... Kaufmann SH, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 113: 4841-52. PMID 19109557 DOI: 10.1182/Blood-2008-08-172726 |
0.355 |
|
| 2009 |
Rau RE, McIntyre E, Kaufmann SH, Espinoza-Delgado I, Karp J, Brown P. Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210-BCR/ABL Expressing Cell Lines. Blood. 114: 2742-2742. DOI: 10.1182/Blood.V114.22.2742.2742 |
0.415 |
|
| 2009 |
Rhodes DR, Kaufmann SH, Meng XW, Wyngaard P, Leopold JS. Abstract A47: Somatic mutations in human cancer cell lines predict sorafenib response Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-A47 |
0.344 |
|
| 2009 |
Haluska P, Carboni J, Asmann Y, Eyck CT, Attar R, Tibodeau J, Hou X, Nakanishi T, Ross D, Kaufmann S, Gottardis M, Erlichman C. Drug efflux by breast cancer resistance protein (BCRP) is a mechanism of resistance to the insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Cancer Research. 69: 2149. DOI: 10.1158/0008-5472.Sabcs-2149 |
0.348 |
|
| 2008 |
Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7900-8. PMID 19047120 DOI: 10.1158/1078-0432.Ccr-08-0415 |
0.306 |
|
| 2008 |
Hendrickson AW, Meng XW, Kaufmann SH. Anticancer therapy: boosting the bang of Bim. The Journal of Clinical Investigation. 118: 3582-4. PMID 18949061 DOI: 10.1172/Jci37553 |
0.385 |
|
| 2008 |
Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation Oncogene. 27: 7223-7234. PMID 18806825 DOI: 10.1038/Onc.2008.360 |
0.373 |
|
| 2008 |
Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Molecular Cancer Therapeutics. 7: 2339-47. PMID 18723481 DOI: 10.1158/1535-7163.Mct-08-0285 |
0.455 |
|
| 2008 |
Ansell SM, Inwards DJ, Rowland KM, Flynn PJ, Morton RF, Moore DF, Kaufmann SH, Ghobrial I, Kurtin PJ, Maurer M, Allmer C, Witzig TE. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer. 113: 508-14. PMID 18543327 DOI: 10.1002/Cncr.23580 |
0.359 |
|
| 2008 |
Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH. Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines. Molecular Pharmacology. 74: 724-35. PMID 18509065 DOI: 10.1124/Mol.108.047787 |
0.383 |
|
| 2008 |
Hackbarth JS, Galvez-Peralta M, Dai NT, Loegering DA, Peterson KL, Meng XW, Karnitz LM, Kaufmann SH. Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I. The Journal of Biological Chemistry. 283: 16711-22. PMID 18408216 DOI: 10.1074/Jbc.M802246200 |
0.313 |
|
| 2008 |
Kaufmann SH, Lee SH, Meng XW, Loegering DA, Kottke TJ, Henzing AJ, Ruchaud S, Samejima K, Earnshaw WC. Apoptosis-associated caspase activation assays. Methods (San Diego, Calif.). 44: 262-72. PMID 18314058 DOI: 10.1016/J.Ymeth.2007.11.005 |
0.36 |
|
| 2008 |
Golovchenko EN, Hanin LG, Kaufmann SH, Tyurin KV, Khanin MA. Dynamics of granzyme B-induced apoptosis: mathematical modeling. Mathematical Biosciences. 212: 54-68. PMID 18249416 DOI: 10.1016/J.Mbs.2007.12.002 |
0.318 |
|
| 2007 |
Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. The Journal of Biological Chemistry. 282: 29831-46. PMID 17698840 DOI: 10.1074/Jbc.M706110200 |
0.428 |
|
| 2007 |
Werneburg NW, Guicciardi ME, Bronk SF, Kaufmann SH, Gores GJ. Tumor necrosis factor-related apoptosis-inducing ligand activates a lysosomal pathway of apoptosis that is regulated by Bcl-2 proteins. The Journal of Biological Chemistry. 282: 28960-70. PMID 17686764 DOI: 10.1074/Jbc.M705671200 |
0.428 |
|
| 2007 |
Ageichik AV, Samejima K, Kaufmann SH, Earnshaw WC. Genetic analysis of the short splice variant of the inhibitor of caspase-activated DNase (ICAD-S) in chicken DT40 cells. The Journal of Biological Chemistry. 282: 27374-82. PMID 17616520 DOI: 10.1074/Jbc.M704307200 |
0.392 |
|
| 2007 |
Mesa RA, Camoriano JK, Geyer SM, Wu W, Kaufmann SH, Rivera CE, Erlichman C, Wright J, Pardanani A, Lasho T, Finke C, Li CY, Tefferi A. A phase II trial of tipifarnib in myelofibrosis: Primary, post-polycythemia vera and post-essential thrombocythemia Leukemia. 21: 1964-1970. PMID 17581608 DOI: 10.1038/Sj.Leu.2404816 |
0.304 |
|
| 2007 |
Kobayashi S, Lee SH, Meng XW, Mott JL, Bronk SF, Werneburg NW, Craig RW, Kaufmann SH, Gores GJ. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. The Journal of Biological Chemistry. 282: 18407-17. PMID 17463001 DOI: 10.1074/Jbc.M610010200 |
0.386 |
|
| 2007 |
Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, Kaufmann SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. The Journal of Biological Chemistry. 282: 8860-72. PMID 17213201 DOI: 10.1074/Jbc.M611777200 |
0.335 |
|
| 2007 |
Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 109: 1387-94. PMID 17082323 DOI: 10.1182/Blood-2006-04-014357 |
0.328 |
|
| 2007 |
Molina JR, Erlichman C, Kaufmann S, Adjei A, Rubin S, Friedman R, Reid J, Qin R, Felten S. A phase I study of lapatinib and topotecan in patients with solid tumors Journal of Clinical Oncology. 25: 3598-3598. DOI: 10.1200/Jco.2007.25.18_Suppl.3598 |
0.372 |
|
| 2007 |
Ricklis RM, Karp JE, Feldman EJ, Galkin S, Greer JM, Ironside V, Mirjafary K, Talbot TD, Morris LE, Wright JJ, Kaufmann SH. In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC). Blood. 110: 914-914. DOI: 10.1182/Blood.V110.11.914.914 |
0.335 |
|
| 2007 |
Shanafelt T, Kaufmann S, Call T, Zent CS, Wu W, Bowen D, Secreto C, Ghosh A, Kabat B, Yang C, Jelinek D, Erlichman C, Kay NE. A Phase 1 Trial of Daily Oral Green Tea Extract in Asymptomatic, Rai Stage 0–II Patients with Chronic Lymphocytic Leukemia. Blood. 110: 2047-2047. DOI: 10.1182/Blood.V110.11.2047.2047 |
0.318 |
|
| 2006 |
Ruchand S, Samejima K, Hudson D, Kaufmann SH, Earnshaw WC. Genetic analysis of apoptotic execution. Sub-Cellular Biochemistry. 40: 75-90. PMID 17623901 DOI: 10.1007/978-1-4020-4896-8_6 |
0.397 |
|
| 2006 |
Henzing AJ, Dodson H, Reid JM, Kaufmann SH, Baxter RL, Earnshaw WC. Synthesis of novel caspase inhibitors for characterization of the active caspase proteome in vitro and in vivo. Journal of Medicinal Chemistry. 49: 7636-45. PMID 17181147 DOI: 10.1021/Jm060385H |
0.407 |
|
| 2006 |
Meng XW, Lee SH, Kaufmann SH. Apoptosis in the treatment of cancer: a promise kept? Current Opinion in Cell Biology. 18: 668-76. PMID 17049222 DOI: 10.1016/J.Ceb.2006.10.008 |
0.4 |
|
| 2006 |
Kaufmann SH. Imatinib spells BAD news for Bcr/abl-positive leukemias Proceedings of the National Academy of Sciences of the United States of America. 103: 14651-14652. PMID 17003111 DOI: 10.1073/Pnas.0607135103 |
0.363 |
|
| 2006 |
Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Molecular Cancer Therapeutics. 5: 2378-87. PMID 16985072 DOI: 10.1158/1535-7163.Mct-06-0235 |
0.45 |
|
| 2006 |
Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Current Treatment Options in Oncology. 7: 285-94. PMID 16916489 DOI: 10.1007/S11864-006-0038-1 |
0.372 |
|
| 2006 |
Mesa R, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 20: 1800-1808. PMID 16871275 DOI: 10.1038/Sj.Leu.2404338 |
0.318 |
|
| 2006 |
Chien J, Aletti G, Baldi A, Catalano V, Muretto P, Keeney GL, Kalli KR, Staub J, Ehrmann M, Cliby WA, Lee YK, Bible KC, Hartmann LC, Kaufmann SH, Shridhar V. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. The Journal of Clinical Investigation. 116: 1994-2004. PMID 16767218 DOI: 10.1172/Jci27698 |
0.386 |
|
| 2006 |
Ravi R, Fuchs EJ, Jain A, Pham V, Yoshimura K, Prouser T, Jalla S, Zhou X, Garrett-Mayer E, Kaufmann SH, Schulick RD, Pardoll DM, Bedi A. Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Research. 66: 1730-9. PMID 16452233 DOI: 10.1158/0008-5472.Can-05-3377 |
0.409 |
|
| 2006 |
Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Research. 66: 362-71. PMID 16397250 DOI: 10.1158/0008-5472.Can-05-1107 |
0.335 |
|
| 2006 |
Loegering DA, Ruchaud S, Earnshaw WC, Kaufmann SH. Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis. Cell Death and Differentiation. 13: 346-7. PMID 16294214 DOI: 10.1038/Sj.Cdd.4401791 |
0.335 |
|
| 2006 |
Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance. Blood. 107: 2501-6. PMID 16291594 DOI: 10.1182/Blood-2005-07-2966 |
0.363 |
|
| 2006 |
Ansell SM, Geyer SM, Kurtin PJ, Inwards DJ, Kaufmann SH, Flynn PJ, Morton RF, Luyun RF, Dakhil SR, Gross H, Witzig TE. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: A phase II trial in the North Central Cancer Treatment Group Journal of Clinical Oncology. 24: 7532-7532. DOI: 10.1200/Jco.2006.24.18_Suppl.7532 |
0.376 |
|
| 2006 |
Witzig TE, Maurer MJ, Johnston PB, Colgan JP, Kaufmann SH, Inwards DJ, Micallef IN, Ansell SM, Zent CS, Allmer C, Weiner GJ, Wooldridge JE, Link BK, Habermann TM. Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274). Blood. 108: 530-530. DOI: 10.1182/Blood.V108.11.530.530 |
0.346 |
|
| 2005 |
Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8403-12. PMID 16322302 DOI: 10.1158/1078-0432.Ccr-05-1201 |
0.348 |
|
| 2005 |
Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 19: 2195-2202. PMID 16224489 DOI: 10.1038/Sj.Leu.2403946 |
0.371 |
|
| 2005 |
Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, Lieberman HB, Chen J, Cliby WA, Kaufmann SH. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Molecular Pharmacology. 68: 1636-44. PMID 16126823 DOI: 10.1124/Mol.105.012716 |
0.387 |
|
| 2005 |
Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5935-41. PMID 16115936 DOI: 10.1158/1078-0432.Ccr-04-2566 |
0.389 |
|
| 2005 |
Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 24: 6861-9. PMID 16007148 DOI: 10.1038/Sj.Onc.1208841 |
0.45 |
|
| 2005 |
Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun R, Flynn PJ, Morton RF, Dakhil SR, Gross H, Kaufmann SH. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma Journal of Clinical Oncology. 23: 5347-5356. PMID 15983389 DOI: 10.1200/Jco.2005.13.466 |
0.362 |
|
| 2005 |
Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 128: 2054-65. PMID 15940637 DOI: 10.1053/J.Gastro.2005.03.010 |
0.348 |
|
| 2005 |
Gore SD, Smith BD, Gojo I, Grever M, Kaufmann SH, Letendre L, Leonard DGB, Marcucci G, Miller CB, Morris L, Piantadosi S, Prior T, Stock W, Karp JE. Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia American Journal of Hematology. 79: 119-127. PMID 15929100 DOI: 10.1002/Ajh.20354 |
0.304 |
|
| 2005 |
Bruzek LM, Poynter JN, Kaufmann SH, Adjei AA. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336). Molecular Pharmacology. 68: 477-86. PMID 15901852 DOI: 10.1124/Mol.104.010074 |
0.365 |
|
| 2005 |
Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, Kaufmann SH, Smith DI, Shridhar V. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer Oncogene. 24: 5089-5100. PMID 15870691 DOI: 10.1038/Sj.Onc.1208700 |
0.364 |
|
| 2005 |
Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3410-6. PMID 15867242 DOI: 10.1158/1078-0432.Ccr-04-2068 |
0.344 |
|
| 2005 |
Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 2149-55. PMID 15788660 DOI: 10.1158/1078-0432.Ccr-04-1673 |
0.302 |
|
| 2005 |
Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 106: 318-27. PMID 15784732 DOI: 10.1182/Blood-2004-09-3523 |
0.428 |
|
| 2005 |
Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1877-83. PMID 15756013 DOI: 10.1158/1078-0432.Ccr-04-1769 |
0.346 |
|
| 2005 |
Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons. Journal of Biological Chemistry. 280: 14349-14355. PMID 15699047 DOI: 10.1074/Jbc.M411890200 |
0.414 |
|
| 2005 |
Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE. Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood. 105: 3722-3730. PMID 15650054 DOI: 10.1182/Blood-2004-10-3999 |
0.357 |
|
| 2005 |
Shanafelt TD, Lee YK, Bone ND, Strege AK, Narayanan VL, Sausville EA, Geyer SM, Kaufmann SH, Kay NE. Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine Blood. 105: 2099-2106. PMID 15388586 DOI: 10.1182/Blood-2004-06-2205 |
0.416 |
|
| 2005 |
Witzig TE, Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH. Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: A phase II trial in the North Central Cancer Treatment Group Journal of Clinical Oncology. 23: 6504-6504. DOI: 10.1200/Jco.2005.23.16_Suppl.6504 |
0.304 |
|
| 2005 |
Erlichman C, Goldberg RM, Mahoney MR, Kabat BF, Huntington JL, Sargent DJ, Sebo TJ, Kaufmann SH, Egner JR, Pitot HC. A phase II trial of CPT-11 in patients (pts) with advanced gastric or gastroesophageal (GE) junction adenocarcinoma (ADCA): A clinical and pharmacodynamic evaluation. A North Central Cancer Treatment Group (NCCTG) Study Journal of Clinical Oncology. 23: 4026-4026. DOI: 10.1200/Jco.2005.23.16_Suppl.4026 |
0.312 |
|
| 2005 |
Mesa RA, Tefferi A, Powell H, Lasho T, Loegering D, Kaufmann SH. JAK2 (V617F) Mutation Status and Neutrophil Apoptotic Resistance in Myelofibrosis with Myeloid Metaplasia (MMM): Correlation and Potential Identification through Phosphorylation Status of STAT3. Blood. 106: 3503-3503. DOI: 10.1182/Blood.V106.11.3503.3503 |
0.366 |
|
| 2004 |
Mesa RA, Tefferi A, Powell H, Lasho T, Kaufmann SH. Ascorbic acid appears to increase the in vitro specificity and sensitivity of arsenic trioxide to the inhibition of primary myeloid colonies from patients with myelofibrosis with myeloid metaplasia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 6619. PMID 28016324 DOI: 10.1200/Jco.2004.22.14_Suppl.6619 |
0.369 |
|
| 2004 |
Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW, Holbeck S, Monks A, Krajewski S, Scudiero DA, Sausville EA, Reed JC, Lazebnik YA, Kaufmann SH. Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6807-20. PMID 15501957 DOI: 10.1158/1078-0432.Ccr-0778-02 |
0.399 |
|
| 2004 |
Ray S, Lu Y, Kaufmann SH, Gustafson WC, Karp JE, Boldogh I, Fields AP, Brasier AR. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. The Journal of Biological Chemistry. 279: 35604-15. PMID 15155749 DOI: 10.1074/Jbc.M401851200 |
0.405 |
|
| 2004 |
Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Research. 64: 3517-3524. PMID 15150106 DOI: 10.1158/0008-5472.Can-03-2770 |
0.433 |
|
| 2004 |
Khanin MA, Lobanov AN, Kaufmann SH. Apoptosis: an optimization approach Computers in Biology and Medicine. 34: 449-459. PMID 15145714 DOI: 10.1016/S0010-4825(03)00089-1 |
0.317 |
|
| 2004 |
Loegering D, Arlander SJ, Hackbarth J, Vroman BT, Roos-Mattjus P, Hopkins KM, Lieberman HB, Karnitz LM, Kaufmann SH. Rad9 protects cells from topoisomerase poison-induced cell death. The Journal of Biological Chemistry. 279: 18641-7. PMID 14988409 DOI: 10.1074/Jbc.M313536200 |
0.419 |
|
| 2004 |
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 103: 3271-7. PMID 14726402 DOI: 10.1182/Blood-2003-08-2764 |
0.397 |
|
| 2004 |
Chien J, Staub J, Hu SI, Erickson-Johnson MR, Couch FJ, Smith DI, Crowl RM, Kaufmann SH, Shridhar V. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer Oncogene. 23: 1636-1644. PMID 14716297 DOI: 10.1038/Sj.Onc.1207271 |
0.383 |
|
| 2004 |
Korfali N, Ruchaud S, Loegering D, Bernard D, Dingwall C, Kaufmann SH, Earnshaw WC. Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis. The Journal of Biological Chemistry. 279: 1030-9. PMID 14583630 DOI: 10.1074/Jbc.M306277200 |
0.403 |
|
| 2004 |
Ghobrial IM, McCormick DJ, Kaufmann SH, Ansell SM, Novak AJ, Stenson MJ, Krajnik KL, Witzig TE. Proteomic analysis of patients with mantle cell lymphoma identifies Hsp90, and other proteins as potential target(s) for drug therapy Journal of Clinical Oncology. 22: 6530-6530. DOI: 10.1200/Jco.2004.22.90140.6530 |
0.324 |
|
| 2004 |
Chandra J, Tracy J, Gorre M, Talpaz M, Griffin J, Verstovsek S, Beran M, Sawyers C, Sausville E, Kaufmann S. Effects of Adaphostin, a Novel Tyrphostin Inhibitor, in Diverse Models of Imatinib Mesylate Resistance. Blood. 104: 2097-2097. DOI: 10.1182/Blood.V104.11.2097.2097 |
0.389 |
|
| 2004 |
Witzig T, Geyer S, Ghobrial I, Inwards D, Fonseca R, Kaufmann S, Kurtin P, Colgan J, Morice W, Alberts S, Salim M, Rowland K, Dakhil S, Morton R, Stella P. Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. Blood. 104: 129-129. DOI: 10.1182/Blood.V104.11.129.129 |
0.359 |
|
| 2004 |
Kaufmann SH. Hopes for kinase inhibitors active against AML take FLT Blood. 103: 8-8. DOI: 10.1182/Blood-2003-10-3514 |
0.328 |
|
| 2003 |
Kalli KR, Devine KE, Cabot MC, Arnt CR, Heldebrant MP, Svingen PA, Erlichman C, Hartmann LC, Conover CA, Kaufmann SH. Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines. Molecular Pharmacology. 64: 1434-1443. PMID 14645674 DOI: 10.1124/Mol.64.6.1434 |
0.45 |
|
| 2003 |
Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 22: 7414-30. PMID 14576849 DOI: 10.1038/Sj.Onc.1206945 |
0.442 |
|
| 2003 |
Arnt CR, Kaufmann SH. The saintly side of Smac/DIABLO: giving anticancer drug-induced apoptosis a boost Cell Death & Differentiation. 10: 1118-1120. PMID 14502234 DOI: 10.1038/Sj.Cdd.4401294 |
0.322 |
|
| 2003 |
Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore SD, Karp JE, Sebolt-Leopold J, Kaufmann SH. Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. The Journal of Biological Chemistry. 278: 47326-39. PMID 12963734 DOI: 10.1074/Jbc.M304793200 |
0.448 |
|
| 2003 |
Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood. 102: 4512-9. PMID 12920036 DOI: 10.1182/Blood-2003-02-0562 |
0.426 |
|
| 2003 |
Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia Leukemia. 17: 849-855. PMID 12750696 DOI: 10.1038/Sj.Leu.2402901 |
0.342 |
|
| 2003 |
Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH, Vokes EE. Phase II Study of the Farnesyl Transferase Inhibitor R115777 in Patients With Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. 21: 1760-1766. PMID 12721252 DOI: 10.1200/Jco.2003.09.075 |
0.331 |
|
| 2003 |
Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. The Journal of Biological Chemistry. 278: 23107-17. PMID 12686563 DOI: 10.1074/Jbc.M302203200 |
0.377 |
|
| 2003 |
Chiorean MV, Yoon J, Bronk SF, Kaufmann SH, Gores GJ. Imatinib mesylate (STI-571), a c-Abl kinase inhibitor, indirectly blocks receptor tyrosine kinase activation and induces apoptosis in a human cholangiocarcinoma cell line Gastroenterology. 124: A742. DOI: 10.1016/S0016-5085(03)83746-0 |
0.404 |
|
| 2002 |
Goldberg RM, Kaufmann SH, Atherton P, Sloan JA, Adjei AA, Pitot HC, Alberts SR, Rubin J, Miller LL, Erlichman C. A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 13: 1674-80. PMID 12377659 DOI: 10.1093/Annonc/Mdf260 |
0.306 |
|
| 2002 |
Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. Journal of Biological Chemistry. 277: 44236-44243. PMID 12218061 DOI: 10.1074/Jbc.M207578200 |
0.392 |
|
| 2002 |
Adjei AA, Reid JM, Erlichman C, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Ruben S, Boemer SA, Atherton P, Ames MM, Kaufmann SH. A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Investigational New Drugs. 20: 297-304. PMID 12201492 DOI: 10.1023/A:1016237426846 |
0.352 |
|
| 2002 |
Kobayashi S, Yamashita K, Takeoka T, Ohtsuki T, Suzuki Y, Takahashi R, Yamamoto K, Kaufmann SH, Uchiyama T, Sasada M, Takahashi A. Calpain-mediated X-linked Inhibitor of Apoptosis Degradation in Neutrophil Apoptosis and Its Impairment in Chronic Neutrophilic Leukemia Journal of Biological Chemistry. 277: 33968-33977. PMID 12121983 DOI: 10.1074/Jbc.M203350200 |
0.392 |
|
| 2002 |
Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells Journal of Clinical Investigation. 110: 91-99. PMID 12093892 DOI: 10.1172/Jci13275 |
0.348 |
|
| 2002 |
Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Molecular Pharmacology. 62: 143-53. PMID 12065765 DOI: 10.1124/Mol.62.1.143 |
0.343 |
|
| 2002 |
Ruchaud S, Korfali N, Villa P, Kottke TJ, Dingwall C, Kaufmann SH, Earnshaw WC. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. The Embo Journal. 21: 1967-77. PMID 11953316 DOI: 10.1093/Emboj/21.8.1967 |
0.397 |
|
| 2002 |
Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 122: 985-93. PMID 11910351 DOI: 10.1053/Gast.2002.32410 |
0.32 |
|
| 2002 |
Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH. Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 99: 664-71. PMID 11781252 DOI: 10.1182/Blood.V99.2.664 |
0.403 |
|
| 2002 |
Chandra J, Mansson E, Gogvadze V, Kaufmann SH, Albertioni F, Orrenius S. Resistance of leukemic cells to 2-chlorodeoxyadenosine is due to a lack of calcium-dependent cytochrome c release. Blood. 99: 655-63. PMID 11781251 DOI: 10.1182/Blood.V99.2.655 |
0.373 |
|
| 2002 |
Meng XW, Heldebrant MP, Kaufmann SH. Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain. Journal of Biological Chemistry. 277: 3776-3783. PMID 11729181 DOI: 10.1074/Jbc.M107218200 |
0.431 |
|
| 2002 |
Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends in Cell Biology. 11: 526-34. PMID 11719060 DOI: 10.1016/S0962-8924(01)02173-0 |
0.335 |
|
| 2002 |
Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function Journal of Biological Chemistry. 277: 1599-1606. PMID 11700302 DOI: 10.1074/Jbc.M106287200 |
0.357 |
|
| 2002 |
Kottke TJ, Blajeski AL, Meng XW, Svingen PA, Ruchaud S, Mesner PW, Boerner SA, Samejima K, Henriquez NV, Chilcote TJ, Lord J, Salmon M, Earnshaw WC, Kaufmann SH. Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. The Journal of Biological Chemistry. 277: 804-15. PMID 11677238 DOI: 10.1074/Jbc.M108419200 |
0.425 |
|
| 2001 |
Kaufmann SH, Kottke TJ, Martins LM, Henzing AJ, Earnshaw WC. Analysis of caspase activation during apoptosis. Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. Unit 18.2. PMID 18228341 DOI: 10.1002/0471143030.Cb1802S11 |
0.364 |
|
| 2001 |
Karp JE, Kaufmann SH, Adjei AA, Lancet JE, Wright JJ, End DW. Current status of clinical trials of farnesyltransferase inhibitors. Current Opinion in Oncology. 13: 470-476. PMID 11673687 DOI: 10.1097/00001622-200111000-00009 |
0.33 |
|
| 2001 |
Mow BMF, Blajeski AL, Chandra J, Kaufmann SH. Apoptosis and the response to anticancer therapy. Current Opinion in Oncology. 13: 453-462. PMID 11673685 DOI: 10.1097/00001622-200111000-00007 |
0.437 |
|
| 2001 |
Blajeski AL, Kottke TJ, Kaufmann SH. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Experimental Cell Research. 270: 277-288. PMID 11640891 DOI: 10.1006/Excr.2001.5349 |
0.431 |
|
| 2001 |
Cowan CM, Thai J, Krajewski S, Reed JC, Nicholson DW, Kaufmann SH, Roskams AJ. Caspases 3 and 9 send a pro-apoptotic signal from synapse to cell body in olfactory receptor neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 7099-109. PMID 11549720 DOI: 10.1523/Jneurosci.21-18-07099.2001 |
0.348 |
|
| 2001 |
Senchenkov A, Han TY, Wang H, Frankel AE, Kottke TJ, Kaufmann SH, Cabot MC. Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT388-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF Blood. 98: 1927-1934. PMID 11535531 DOI: 10.1182/Blood.V98.6.1927 |
0.419 |
|
| 2001 |
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I. Clinical and biologic activity of the famesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial Blood. 97: 3361-3369. PMID 11369625 DOI: 10.1182/Blood.V97.11.3361 |
0.34 |
|
| 2001 |
Boerner SA, Tourne ME, Kaufmann SH, Bible KC. Effect of P-glycoprotein on flavopiridol sensitivity. British Journal of Cancer. 84: 1391-1396. PMID 11355953 DOI: 10.1054/Bjoc.2000.1688 |
0.386 |
|
| 2001 |
Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic Hepatology. 34: 3-6. DOI: 10.1053/Jhep.2001.25173A |
0.311 |
|
| 2000 |
Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, Kaufmann SH, Gores GJ. Cathepsin B contributes to TNF-α–mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c Journal of Clinical Investigation. 106: 1127-1137. PMID 11067865 DOI: 10.1172/Jci9914 |
0.343 |
|
| 2000 |
Kaufmann SH, Gores GJ. Apoptosis in cancer: Cause and cure Bioessays. 22: 1007-1017. PMID 11056477 DOI: 10.1002/1521-1878(200011)22:11<1007::Aid-Bies7>3.0.Co;2-4 |
0.409 |
|
| 2000 |
Thangaraju M, Kaufmann SH, Couch FJ. BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. Journal of Biological Chemistry. 275: 33487-33496. PMID 10938285 DOI: 10.1074/Jbc.M005824200 |
0.413 |
|
| 2000 |
Kaufmann SH, Mesner PW, Samejima K, Toné S, Earnshaw WC. Detection of DNA cleavage in apoptotic cells. Methods in Enzymology. 322: 3-15. PMID 10914000 DOI: 10.1016/S0076-6879(00)22003-X |
0.372 |
|
| 2000 |
Burtelow MA, Kaufmann SH, Karnitz LM. Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage. Journal of Biological Chemistry. 275: 26343-26348. PMID 10852904 DOI: 10.1074/Jbc.M001244200 |
0.315 |
|
| 2000 |
Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Experimental Cell Research. 256: 42-9. PMID 10739650 DOI: 10.1006/Excr.2000.4838 |
0.415 |
|
| 2000 |
Budihardjo II, Boerner SA, Eckdahl S, Svingen PA, Rios R, Ames MM, Kaufmann SH. Effect of 6-aminonicotinamide and other protein synthesis inhibitors on formation of platinum-DNA adducts and cisplatin sensitivity. Molecular Pharmacology. 57: 529-38. PMID 10692493 DOI: 10.1124/Mol.57.3.529 |
0.408 |
|
| 2000 |
Svingen PA, Karp JE, Krajewski S, Mesner PW, Gore SD, Burke PJ, Reed JC, Lazebnik YA, Kaufmann SH. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia Blood. 96: 3922-3931. DOI: 10.1182/Blood.V96.12.3922.H8003922_3922_3931 |
0.343 |
|
| 2000 |
Torok NJ, Kottke TJ, Kaufmann SH, LaRusso NF, Gores GJ, Clin M. Nitric oxide (NO) inhibits apoptosis in cholangiocarcinoma cells by blocking caspase 9 activation Gastroenterology. 118. DOI: 10.1016/S0016-5085(00)85990-9 |
0.363 |
|
| 1999 |
Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annual Review of Biochemistry. 68: 383-424. PMID 10872455 DOI: 10.1146/Annurev.Biochem.68.1.383 |
0.423 |
|
| 1999 |
Walker DL, Reid JM, Svingen PA, Rios R, Covey JM, Alley MC, Hollingshead MG, Budihardjo II, Eckdahl S, Boerner SA, Kaufmann SH, Ames MM. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent. Biochemical Pharmacology. 58: 1057-66. PMID 10509758 DOI: 10.1016/S0006-2952(99)00179-3 |
0.325 |
|
| 1999 |
Mesner PW, Bible KC, Martins LM, Kottke TJ, Srinivasula SM, Svingen PA, Chilcote TJ, Basi GS, Tung JS, Krajewski S, Reed JC, Alnemri ES, Earnshaw WC, Kaufmann SH. Characterization of caspase processing and activation in HL-60 cell cytosol under cell-free conditions. Nucleotide requirement and inhibitor profile. The Journal of Biological Chemistry. 274: 22635-45. PMID 10428844 DOI: 10.1074/Jbc.274.32.22635 |
0.402 |
|
| 1999 |
Kottke TJ, Blajeski AL, Martins LM, Mesner PW, Davidson NE, Earnshaw WC, Armstrong DK, Kaufmann SH. Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. The Journal of Biological Chemistry. 274: 15927-36. PMID 10336499 DOI: 10.1074/Jbc.274.22.15927 |
0.433 |
|
| 1999 |
Samejima K, Svingen PA, Basi GS, Kottke T, Mesner PW, Stewart L, Durrieu F, Poirier GG, Alnemri ES, Champoux JJ, Kaufmann SH, Earnshaw WC. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. The Journal of Biological Chemistry. 274: 4335-40. PMID 9933635 DOI: 10.1074/Jbc.274.7.4335 |
0.418 |
|
| 1999 |
Faubion WA, Guicciardi ME, Miyoshi H, Bronk SF, Roberts PJ, Svingen PA, Kaufmann SH, Gores GJ. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas Journal of Clinical Investigation. 103: 137-145. PMID 9884343 DOI: 10.1172/Jci4765 |
0.397 |
|
| 1999 |
Yamashita K, Takahashi A, Kobayashi S, Hirata H, Mesner PW, Kaufmann SH, Yonehara S, Yamamoto K, Uchiyama T, Sasada M. Caspases Mediate Tumor Necrosis Factor-–Induced Neutrophil Apoptosis and Downregulation of Reactive Oxygen Production Blood. 93: 674-685. DOI: 10.1182/Blood.V93.2.674.402K26_674_685 |
0.358 |
|
| 1998 |
Martins LM, Kottke TJ, Kaufmann SH, Earnshaw WC. Phosphorylated forms of activated caspases are present in cytosol from HL-60 cells during etoposide-induced apoptosis. Blood. 92: 3042-9. PMID 9787137 DOI: 10.1182/Blood.V92.9.3042 |
0.39 |
|
| 1998 |
Mullany S, Svingen PA, Kaufmann SH, Erlichman C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemotherapy and Pharmacology. 42: 391-399. PMID 9771954 DOI: 10.1007/S002800050835 |
0.385 |
|
| 1998 |
Samejima K, Toné S, Kottke TJ, Enari M, Sakahira H, Cooke CA, Durrieu F, Martins LM, Nagata S, Kaufmann SH, Earnshaw WC. Transition from caspase-dependent to caspase-independent mechanisms at the onset of apoptotic execution. The Journal of Cell Biology. 143: 225-39. PMID 9763434 DOI: 10.1083/Jcb.143.1.225 |
0.386 |
|
| 1998 |
Kaufmann SH. Cell death induced by topoisomerase-targeted drugs: More questions than answers Biochimica Et Biophysica Acta - Gene Structure and Expression. 1400: 195-211. PMID 9748575 DOI: 10.1016/S0167-4781(98)00136-5 |
0.393 |
|
| 1998 |
Karnes W.E. J, Weller SG, Adjei PN, Kottke TJ, Glenn KS, Gores GJ, Kaufmann SH. Inhibition of epidermal growth factor receptor kinase induces protease- dependent apoptosis in human colon cancer cells Gastroenterology. 114: 930-939. PMID 9558281 DOI: 10.1016/S0016-5085(98)70312-9 |
0.392 |
|
| 1998 |
Budihardjo II, Poirier GG, Kaufmann SH. Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody. Molecular and Cellular Biochemistry. 178: 245-9. PMID 9546606 DOI: 10.1023/A:1006808001462 |
0.35 |
|
| 1998 |
Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC. Elevated Expression of the Apoptotic Regulator Mcl-1 at the Time of Leukemic Relapse Blood. 91: 991-1000. DOI: 10.1182/Blood.V91.3.991.991_991_1000 |
0.36 |
|
| 1997 |
Kaufmann SH. Resistance to topoisomerase II poisons: Is the answer in the promoter? Leukemia Research. 21: 1033-1036. PMID 9444936 DOI: 10.1016/S0145-2126(97)00067-2 |
0.341 |
|
| 1997 |
Martins LM, Mesner PW, Kottke TJ, Basi GS, Sinha S, Tung JS, Svingen PA, Madden BJ, Takahashi A, McCormick DJ, Earnshaw WC, Kaufmann SH. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood. 90: 4283-96. PMID 9373239 DOI: 10.1182/Blood.V90.11.4283.4283_4283_4296 |
0.415 |
|
| 1997 |
Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspase inhibitors. Trends in Biochemical Sciences. 22: 388-93. PMID 9357314 DOI: 10.1016/S0968-0004(97)01107-9 |
0.365 |
|
| 1997 |
Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 90: 935-43. PMID 9242521 DOI: 10.1182/Blood.V90.3.935.935_935_943 |
0.431 |
|
| 1997 |
Mesner PW, Budihardjo II, Kaufmann SH. Chemotherapy-induced apoptosis. Advances in Pharmacology (San Diego, Calif.). 41: 461-99. PMID 9204156 DOI: 10.1016/S1054-3589(08)61069-8 |
0.431 |
|
| 1997 |
Mesner PW, Kaufmann SH. Methods utilized in the study of apoptosis. Advances in Pharmacology. 41: 57-87. PMID 9204141 DOI: 10.1016/S1054-3589(08)61054-6 |
0.345 |
|
| 1997 |
Kellner U, Hutchinson L, Seidel A, Lage H, Danks MK, Dietel M, Kaufmann SH. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. International Journal of Cancer. 71: 817-824. PMID 9180151 DOI: 10.1002/(Sici)1097-0215(19970529)71:5<817::Aid-Ijc20>3.0.Co;2-3 |
0.327 |
|
| 1997 |
Martins LM, Kottke T, Mesner PW, Basi GS, Sinha S, Frigon N, Tatar E, Tung JS, Bryant K, Takahashi A, Svingen PA, Madden BJ, McCormick DJ, Earnshaw WC, Kaufmann SH. Activation of multiple interleukin-1beta converting enzyme homologues in cytosol and nuclei of HL-60 cells during etoposide-induced apoptosis. The Journal of Biological Chemistry. 272: 7421-30. PMID 9054443 DOI: 10.1074/Jbc.272.11.7421 |
0.396 |
|
| 1997 |
Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng YC, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells Blood. 89: 2098-2104. DOI: 10.1182/Blood.V89.6.2098 |
0.352 |
|
| 1996 |
Adjei PN, Kaufmann SH, Leung WY, Mao F, Gores GJ. Selective induction of apoptosis in hep 3B cells by topoisomerase I inhibitors: Evidence for a protease-dependent pathway that does not activate cysteine protease P32 Journal of Clinical Investigation. 98: 2588-2596. PMID 8958222 DOI: 10.1172/Jci119078 |
0.432 |
|
| 1996 |
Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. Journal of Clinical Oncology. 14: 3074-3084. PMID 8955652 DOI: 10.1200/Jco.1996.14.12.3074 |
0.311 |
|
| 1996 |
Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun SC, Kumar R. Bcl-2 prevents CD95 (Fas/APO-1)-induced degradation of lamin B and poly(ADP-ribose) polymerase and restores the NF-kappaB signaling pathway. The Journal of Biological Chemistry. 271: 30354-9. PMID 8939996 DOI: 10.1074/Jbc.271.48.30354 |
0.326 |
|
| 1996 |
Desnoyers S, Kaufmann SH, Poirier GG. Alteration of the nucleolar localization of poly(ADP-ribose) polymerase upon treatment with transcription inhibitors. Experimental Cell Research. 227: 146-53. PMID 8806461 DOI: 10.1006/Excr.1996.0259 |
0.312 |
|
| 1996 |
Kaufmann SH. Proteolytic cleavage during chemotherapy-induced apoptosis Molecular Medicine Today. 2: 298-303. PMID 8796910 DOI: 10.1016/1357-4310(96)10023-X |
0.419 |
|
| 1996 |
Takahashi A, Alnemri ES, Lazebnik YA, Fernandes-Alnemri T, Litwack G, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 93: 8395-400. PMID 8710882 DOI: 10.1073/Pnas.93.16.8395 |
0.318 |
|
| 1996 |
Ubol S, Park S, Budihardjo I, Desnoyers S, Montrose MH, Poirier GG, Kaufmann SH, Griffin DE. Temporal changes in chromatin, intracellular calcium, and poly(ADP-ribose) polymerase during Sindbis virus-induced apoptosis of neuroblastoma cells. Journal of Virology. 70: 2215-20. PMID 8642645 DOI: 10.1128/Jvi.70.4.2215-2220.1996 |
0.359 |
|
| 1996 |
Kaufmann SH, Peereboom DM, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK. Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines Journal of the National Cancer Institute. 88: 734-741. PMID 8637027 DOI: 10.1093/Jnci/88.11.734 |
0.358 |
|
| 1996 |
Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. The Faseb Journal. 10: 587-597. PMID 8621058 DOI: 10.1096/Fasebj.10.5.8621058 |
0.349 |
|
| 1996 |
Carow C, Levenstein M, Kaufmann S, Chen J, Amin S, Rockwell P, Witte L, Borowitz M, Civin C, Small D. Expression of the hematopoietic growth factor receptor FLT3 (STK- 1/Flk2) in human leukemias Blood. 87: 1089-1096. DOI: 10.1182/Blood.V87.3.1089.Bloodjournal8731089 |
0.334 |
|
| 1995 |
Sha EC, Sha MC, Kaufmann SH. Evaluation of 2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl) hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro Investigational New Drugs. 13: 285-294. PMID 8824346 DOI: 10.1007/Bf00873134 |
0.385 |
|
| 1995 |
Shah GM, Kaufmann SH, Poirier GG. Detection of poly(ADP-ribose) polymerase and its apoptosis-specific fragment by a nonisotopic activity-western blot technique. Analytical Biochemistry. 232: 251-4. PMID 8747484 DOI: 10.1006/Abio.1995.0016 |
0.322 |
|
| 1995 |
Lazebnik YA, Takahashi A, Poirier GG, Kaufmann SH, Earnshaw WC. Characterization of the execution phase of apoptosis in vitro using extracts from condemned-phase cells. Journal of Cell Science. Supplement. 19: 41-9. PMID 8655646 DOI: 10.1242/Jcs.1995.Supplement_19.6 |
0.391 |
|
| 1995 |
Doyle LA, Ross DD, Sridhara R, Fojo AT, Kaufmann SH, Lee EJ, Schiffer CA. Expression of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells. British Journal of Cancer. 71: 52-8. PMID 7819048 DOI: 10.1038/Bjc.1995.11 |
0.335 |
|
| 1995 |
Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proceedings of the National Academy of Sciences of the United States of America. 92: 9042-6. PMID 7568069 DOI: 10.1073/Pnas.92.20.9042 |
0.398 |
|
| 1995 |
Jones R, Barber J, Vala, Collector M, Kaufmann S, Ludeman S, Colvin O, Hilton J. Assessment of aldehyde dehydrogenase in viable cells Blood. 85: 2742-2746. DOI: 10.1182/Blood.V85.10.2742.Bloodjournal85102742 |
0.336 |
|
| 1995 |
Schneider E, Cowan K, Bader H, Toomey S, Schwartz G, Karp J, Burke P, Kaufmann S. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia Blood. 85: 186-193. DOI: 10.1182/Blood.V85.1.186.Bloodjournal851186 |
0.335 |
|
| 1994 |
Peereboom D, Charron M, Kaufmann SH. Topoisomerases in human leukemia Advances in Pharmacology (San Diego, Calif.). 29: 33-50. PMID 8996600 DOI: 10.1016/S1054-3589(08)61130-8 |
0.356 |
|
| 1994 |
Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 371: 346-7. PMID 8090205 DOI: 10.1038/371346A0 |
0.305 |
|
| 1994 |
Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology. 12: 2193-2203. PMID 7931489 DOI: 10.1200/Jco.1994.12.10.2193 |
0.32 |
|
| 1994 |
Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC. Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemotherapy and Pharmacology. 34. PMID 7520844 DOI: 10.1007/Bf00684864 |
0.323 |
|
| 1994 |
Kaufmann S, Karp J, Jones R, Miller C, Schneider E, Zwelling L, Cowan K, Wendel K, Burke P. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia Blood. 83: 517-530. DOI: 10.1182/Blood.V83.2.517.517 |
0.327 |
|
| 1993 |
Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. The Current Status of Camptothecin Analogues as Antitumor Agents Journal of the National Cancer Institute. 85: 271-291. PMID 8381186 DOI: 10.1093/Jnci/85.4.271 |
0.378 |
|
| 1992 |
Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 647-56. PMID 1312588 DOI: 10.1200/Jco.1992.10.4.647 |
0.306 |
|
| 1991 |
Kaufmann SH, Brunet G, Talbot B, Lamarr D, Dumas C, Shaper JH, Poirier G. Association of poly(ADP-ribose) polymerase with the nuclear matrix: the role of intermolecular disulfide bond formation, RNA retention, and cell type. Experimental Cell Research. 192: 524-35. PMID 1703086 DOI: 10.1016/0014-4827(91)90072-3 |
0.303 |
|
| 1989 |
Leach KL, Powers EA, Ruff VA, Jaken S, Kaufmann S. Type 3 protein kinase C localization to the nuclear envelope of phorbol ester-treated NIH 3T3 cells. The Journal of Cell Biology. 109: 685-95. PMID 2668302 DOI: 10.1083/Jcb.109.2.685 |
0.358 |
|
| 1982 |
Kaufmann SH, Quddus FF, Shaper JH. An Alternative Approach to the Quantitation of Glucocorticoid-Receptor Complexes in the Nuclei of Lymphoid Cells Endocrinology. 110: 708-716. PMID 7056227 DOI: 10.1210/Endo-110-3-708 |
0.31 |
|
| Show low-probability matches. |